Literature DB >> 26269619

New Real-Time PCR Assays for Detection of Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Group.

Shamira J Shallom1, Natalia S Moura1, Kenneth N Olivier2, Elizabeth P Sampaio3, Steven M Holland4, Adrian M Zelazny5.   

Abstract

Members of the Mycobacterium abscessus group (MAG) cause lung, soft tissue, and disseminated infections. The oral macrolides clarithromycin and azithromycin are commonly used for treatment. MAG can display clarithromycin resistance through the inducible erm(41) gene or via acquired mutations in the rrl (23S rRNA) gene. Strains harboring a truncation or a T28C substitution in erm(41) lose the inducible resistance trait. Phenotypic detection of clarithromycin resistance requires extended incubation (14 days), highlighting the need for faster methods to detect resistance. Two real-time PCR-based assays were developed to assess inducible and acquired clarithromycin resistance and tested on a total of 90 clinical and reference strains. A SYBR green assay was designed to distinguish between a full-length and truncated erm(41) gene by temperature shift in melting curve analysis. Single nucleotide polymorphism (SNP) allele discrimination assays were developed to distinguish T or C at position 28 of erm(41) and 23S rRNA rrl gene mutations at position 2058 and/or 2059. Truncated and full-size erm(41) genes were detected in 21/90 and 69/90 strains, respectively, with 64/69 displaying T at nucleotide position 28 and 5/69 containing C at that position. Fifteen isolates showed rrl mutations conferring clarithromycin resistance, including A2058G (11 isolates), A2058C (3 isolates), and A2059G (1 isolate). Targeted sequencing and phenotypic assessment of resistance concurred with molecular assay results. Interestingly, we also noted cooccurring strains harboring an active erm(41), inactive erm(41), and/or acquired mutational resistance, as well as slowly growing MAG strains and also strains displaying an inducible resistance phenotype within 5 days, long before the recommended 14-day extended incubation.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26269619      PMCID: PMC4609725          DOI: 10.1128/JCM.01714-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns.

Authors:  Hee-Youn Kim; Byoung Jun Kim; Yoonwon Kook; Yeo-Jun Yun; Jeong Hwan Shin; Bum-Joon Kim; Yoon-Hoh Kook
Journal:  Microbiol Immunol       Date:  2010-06       Impact factor: 1.955

2.  Phylogenetic sequence variations in bacterial rRNA affect species-specific susceptibility to drugs targeting protein synthesis.

Authors:  Subramanian Akshay; Mihai Bertea; Sven N Hobbie; Björn Oettinghaus; Dimitri Shcherbakov; Erik C Böttger; Rashid Akbergenov
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

Review 3.  Mycobacterium abscessus: challenges in diagnosis and treatment.

Authors:  Jeana L Benwill; Richard J Wallace
Journal:  Curr Opin Infect Dis       Date:  2014-12       Impact factor: 4.915

4.  Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus.

Authors:  Florian P Maurer; Claudio Castelberg; Chantal Quiblier; Erik C Böttger; Akos Somoskövi
Journal:  J Antimicrob Chemother       Date:  2014-02-04       Impact factor: 5.790

5.  Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.

Authors:  Sylvaine Bastian; Nicolas Veziris; Anne-Laure Roux; Florence Brossier; Jean-Louis Gaillard; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

6.  Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains.

Authors:  Edouard Macheras; Anne-Laure Roux; Sylvaine Bastian; Sylvia Cardoso Leão; Moises Palaci; Valérie Sivadon-Tardy; Cristina Gutierrez; Elvira Richter; Sabine Rüsch-Gerdes; Gaby Pfyffer; Thomas Bodmer; Emmanuelle Cambau; Jean-Louis Gaillard; Beate Heym
Journal:  J Clin Microbiol       Date:  2010-11-24       Impact factor: 5.948

7.  Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs.

Authors:  Barbara A Brown-Elliott; Sruthi Vasireddy; Ravikiran Vasireddy; Elena Iakhiaeva; Susan T Howard; Kevin Nash; Nicholas Parodi; Anita Strong; Martha Gee; Terry Smith; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

8.  A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.

Authors:  Kevin A Nash; Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

9.  Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii.

Authors:  Adrian M Zelazny; Jeremy M Root; Yvonne R Shea; Rhonda E Colombo; Isdore C Shamputa; Frida Stock; Sean Conlan; Steven McNulty; Barbara A Brown-Elliott; Richard J Wallace; Kenneth N Olivier; Steven M Holland; Elizabeth P Sampaio
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

10.  Detection and assessment of clarithromycin inducible resistant strains among Korean Mycobacterium abscessus clinical strains: PCR methods.

Authors:  Seung-Heon Lee; Hee Kyung Yoo; Seol Hee Kim; Won-Jung Koh; Chang Ki Kim; Young Kil Park; Hee Jin Kim
Journal:  J Clin Lab Anal       Date:  2014-03-20       Impact factor: 2.352

View more
  14 in total

1.  Whole-Genome Sequencing for Predicting Clarithromycin Resistance in Mycobacterium abscessus.

Authors:  Samuel Lipworth; Natasha Hough; Laura Leach; Marcus Morgan; Katie Jeffery; Monique Andersson; Esther Robinson; E Grace Smith; Derrick Crook; Tim Peto; Timothy Walker
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Soyoun Shin; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research.

Authors:  Shelby Daniel-Wayman; Getahun Abate; Daniel L Barber; Luiz E Bermudez; Rhea N Coler; Michael H Cynamon; Charles L Daley; Rebecca M Davidson; Thomas Dick; R Andres Floto; Emily Henkle; Steven M Holland; Mary Jackson; Richard E Lee; Eric L Nuermberger; Kenneth N Olivier; Diane J Ordway; D Rebecca Prevots; James C Sacchettini; Max Salfinger; Christopher M Sassetti; Christine F Sizemore; Kevin L Winthrop; Adrian M Zelazny
Journal:  Am J Respir Crit Care Med       Date:  2019-04-15       Impact factor: 21.405

Review 4.  Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for the Rapid Detection of Antimicrobial Resistance Mechanisms and Beyond.

Authors:  Marina Oviaño; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

5.  Clonal Diversification and Changes in Lipid Traits and Colony Morphology in Mycobacterium abscessus Clinical Isolates.

Authors:  In Kwon Park; Amy P Hsu; Hervé Tettelin; Shamira J Shallom; Steven K Drake; Li Ding; Un-In Wu; Nick Adamo; D Rebecca Prevots; Kenneth N Olivier; Steven M Holland; Elizabeth P Sampaio; Adrian M Zelazny
Journal:  J Clin Microbiol       Date:  2015-08-19       Impact factor: 5.948

6.  Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Hyun Lee; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

7.  Detection of Mixed Populations of Clarithromycin-Susceptible and -Resistant Mycobacterium abscessus Strains.

Authors:  Shamira J Shallom; Adrian M Zelazny
Journal:  J Clin Microbiol       Date:  2022-03-22       Impact factor: 11.677

Review 8.  Mycobacterium abscessus: Shapeshifter of the Mycobacterial World.

Authors:  Keenan Ryan; Thomas F Byrd
Journal:  Front Microbiol       Date:  2018-11-01       Impact factor: 5.640

9.  Prevalence of nontuberculous mycobacteria and high efficacy of d-cycloserine and its synergistic effect with clarithromycin against Mycobacterium fortuitum and Mycobacterium abscessus.

Authors:  Azar Dokht Khosravi; Mehdi Mirsaeidi; Abbas Farahani; Mohammad Reza Tabandeh; Parviz Mohajeri; Saeed Shoja; Seyedeh Roghayeh Hoseini Lar KhosroShahi
Journal:  Infect Drug Resist       Date:  2018-12-07       Impact factor: 4.003

10.  Hydroalcoholic Extract and Ethyl Acetate Fraction of Bixa orellana Leaves Decrease the Inflammatory Response to Mycobacterium abscessus Subsp. massiliense.

Authors:  José Lima Viana; Adrielle Zagmignan; Luís Felipe Lima Lobato; Afonso Gomes Abreu; Luís Cláudio Nascimento da Silva; Joicy Cortez de Sá; Cristina de Andrade Monteiro; João Henrique Ghilardi Lago; Letícia Machado Gonçalves; Rafael Cardoso Carvalho; Lídio Gonçalves Lima Neto; Eduardo Martins de Sousa
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-02       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.